Myomo (MYO) investor relations material

Strategic positioning and market opportunity

• Holds first-mover advantage in wearable robotics for upper extremity paralysis, with exclusive Medicare billing codes L8701 and L8702.

• Targets a large U.S. market, with 400,000–800,000 potential candidates and 40,000–80,000 new annual incidence cases post-stroke.

• Focus shifting from prevalence (chronic) to incidence (recent) stroke populations to improve motivation and outcomes.

• Recurring revenue sources prioritized through MyoConnect program and referral channels.

• Expanding payer contracts, including a major deal with Elevance, now covering 158 million lives.

Product innovation and clinical validation

• MyoPro Myoelectric Orthosis uses non-invasive sensors to amplify electromyogram signals, enabling voluntary arm movement.

• Supported by 35 patents, with the latest MyoPro 2x launched in 2025 and a mobile app reducing device costs.

• Clinical studies and a Medicare-focused registry show significant improvements in upper extremity function.

• A randomized controlled trial at University of Utah is underway to further validate outcomes and influence payer policies.

Go-to-market and operational strategy

• Direct billing channel generates 70% of revenue, leveraging advertising, referrals, and partnerships with O&P providers.

• Custom fabrication process includes telehealth screening, physician prescription, and 3D-printed orthotic components.

• Plans to insource 3D printing in 2026 for cost reduction.

• MyoCare coaches and trained therapists support patient onboarding and device use.